These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21985586)

  • 1. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.
    Zanger P; Kötter I; Kremsner PG; Gabrysch S
    Clin Microbiol Infect; 2012 Jul; 18(7):670-6. PubMed ID: 21985586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
    Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmaniasis in the era of tumor necrosis factor alpha antagonist therapy--a research agenda for Europe.
    Zanger P; Gabrysch S
    Euro Surveill; 2013 Jul; 18(30):20542. PubMed ID: 23929182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous leishmaniasis in a patient receiving infliximab.
    Hernández-Torres A; García-Vázquez E; Frías-Iniesta J; Herrero-Martínez JA; Gómez-Gómez J
    Scand J Infect Dis; 2013 Jul; 45(7):567-9. PubMed ID: 23270475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
    Denys BG; Bogaerts Y; Coenegrachts KL; De Vriese AS
    Clin Sci (Lond); 2007 Mar; 112(5):281-9. PubMed ID: 17261090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
    Strangfeld A; Listing J
    Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update upon efficacy and safety of TNF-α inhibitors.
    Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
    Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
    Jain VV; Evans T; Peterson MW
    Respir Med; 2006 Jul; 100(7):1291-3. PubMed ID: 16545951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA; van Olffen GH; Hageman G
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
    Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
    Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.